Goldman Sachs: Alibaba Health's performance guidance for the fiscal year 2026 is expected to continue to have an upside potential. The target price has been raised to 5.2 Hong Kong dollars.

Goldman Sachs released a research report stating that after Alibaba Health disclosed its mid-term performance for the fiscal year ending September 2026, the firm maintained its "neutral" rating. The main reasons include the company benefiting from structural advantages in the industry, such as the flow of original prescription drugs from hospital channels and the accelerated growth of online drug penetration rate. Goldman Sachs has slightly adjusted Alibaba Health's revenue forecast for the fiscal years 2026 to 2028 to grow by 2% to 4%; and correspondingly raised the adjusted net profit forecast by 2% to 4%. Based on a 28 times price-earnings ratio forecast for its pharmacy and medical services business in 2027, the target price has been raised from 4.7 Hong Kong dollars to 5.2 Hong Kong dollars, maintaining a "neutral" rating.